Korean J Radiol.
2022 Jul;23(7):697-719. 10.3348/kjr.2021.0593.
Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting
- Affiliations
-
- 1Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore
- 2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
- 3Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei City & Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- 4Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- 5Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 6Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Medical Imaging, Shanghai, China
- 7Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
- 8Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
- 9Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan
- 10Department of Gastroenterology, The University of Tokyo Hospital, Tokyo, Japan
- KMID: 2530756
- DOI: http://doi.org/10.3348/kjr.2021.0593
Abstract
- Gadoxetate magnetic resonance imaging (MRI) is widely used in clinical practice for liver imaging. For optimal use, we must understand both its advantages and limitations. This article is the outcome of an online advisory board meeting and subsequent discussions by a multidisciplinary group of experts on liver diseases across the Asia-Pacific region, first held on September 28, 2020. Here, we review the technical considerations for the use of gadoxetate, its current role in the management of patients with hepatocellular carcinoma (HCC), and its relevance in consensus guidelines for HCC imaging diagnosis. In the latter part of this review, we examine recent evidence evaluating the impact of gadoxetate on clinical outcomes on a continuum from diagnosis to treatment decision-making and follow-up. In conclusion, we outline the potential future roles of gadoxetate MRI based on an evolving understanding of the clinical utility of this contrast agent in the management of patients at risk of, or with, HCC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Comprehensive Review of Hepatocellular Carcinoma Enhancement Patterns in MRI: Emphasis on Gadoxetate-Enhanced Imaging
- Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology
- 11th Combined Meeting Asia Pacific Spine Society & Asia Pacific Paediatric Orthopaedic Society
- Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging
- The 10th Anniversary of Asia Pacific Allergy
